Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.

Miyajima, K ; Minatoguchi, S ; et al.

In: Hypertension research : official journal of the Japanese Society of Hypertension, Jg. 30 (2007-04-01), Heft 4, S. 307-13

academicJournal

Wie komme ich dran?

QT dispersion has been reported to increase in patients with essential hypertension, and abnormal QT dispersion is associated with arrythmias and sudden cardiac death. However, whether change in QT dispersion is related to oxidative stress is unclear. We examined the effect of the angiotensin II receptor blocker valsartan on QT dispersion and the relationship between oxidative stress and QT dispersion in patients with essential hypertension. Hypertensive patients whose systolic blood pressure (SBP) was more than 140 mmHg and/or diastolic blood pressure (DBP) was more than 90 mmHg were treated with valsartan. Blood pressure was measured once a month for 6 months. The difference between the maximal and minimal QT intervals within a 12-lead surface ECG was measured and QT dispersion and QTc dispersion corrected by heart rate were obtained before and 6 months after treatment. Left ventricular mass (LVM) assessed by echocardiography was obtained at baseline and 6 months after treatment. Venous blood samples were obtained at baseline and 6 months after treatment to measure serum levels of lipoperoxidation (LPO) and type I and III procollagen. Treatment with valsartan significantly decreased SBP and DBP. QTc dispersion decreased significantly 6 months after treatment with valsartan as compared to the baseline values. Valsartan treatment did not affect the LVM. Valsartan significantly decreased the abnormally high LPO levels. The changes in QTc dispersion were positively correlated with changes in the serum levels of LPO and with changes in DBP. The correlation between changes in LPO and QTc dispersion was more close than that between changes in DBP and QTc dispersion. In conclusion, antihypertensive therapy with valsartan reduces QTc dispersion and this may be related to the ability of valsartan to reduce oxidative stress in patients with essential hypertension.

Titel:	Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Autor/in / Beteiligte Person:	Miyajima, K ; Minatoguchi, S ; Ito, Y ; Hukunishi, M ; Matsuno, Y ; Kakami, M ; Kawasaki, M ; Nishigaki, K ; Takemura, G ; Fujiwara, H
Zeitschrift:	Hypertension research : official journal of the Japanese Society of Hypertension, Jg. 30 (2007-04-01), Heft 4, S. 307-13
Veröffentlichung:	2009- : London : Nature Publishing Group ; <i>Original Publication</i>: Toyonaka, Japan : The Society, c1992-2003, 2007
Medientyp:	academicJournal
ISSN:	0916-9636 (print)
DOI:	10.1291/hypres.30.307
Schlagwort:	Aged Angiotensin II Type 1 Receptor Blockers therapeutic use Antihypertensive Agents therapeutic use Blood Pressure drug effects Blood Pressure physiology Collagen Type I blood Collagen Type III blood Female Follow-Up Studies Heart Rate drug effects Heart Rate physiology Humans Hypertension drug therapy Hypertrophy, Left Ventricular physiopathology Lipid Peroxidation drug effects Lipid Peroxidation physiology Long QT Syndrome physiopathology Long QT Syndrome prevention & control Male Oxidative Stress physiology Prospective Studies Tetrazoles therapeutic use Valine pharmacology Valine therapeutic use Valsartan Angiotensin II Type 1 Receptor Blockers pharmacology Antihypertensive Agents pharmacology Electrocardiography Hypertension physiopathology Oxidative Stress drug effects Tetrazoles pharmacology Valine analogs & derivatives
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Clinical Trial; Journal Article Language: English [Hypertens Res] 2007 Apr; Vol. 30 (4), pp. 307-13. MeSH Terms: Electrocardiography* ; Angiotensin II Type 1 Receptor Blockers / pharmacology ; Antihypertensive Agents / pharmacology ; Hypertension / physiopathology ; Oxidative Stress / drug effects ; Tetrazoles / pharmacology ; Valine / analogs & derivatives ; Aged ; Angiotensin II Type 1 Receptor Blockers / therapeutic use ; Antihypertensive Agents / therapeutic use ; Blood Pressure / drug effects ; Blood Pressure / physiology ; Collagen Type I / blood ; Collagen Type III / blood ; Female ; Follow-Up Studies ; Heart Rate / drug effects ; Heart Rate / physiology ; Humans ; Hypertension / drug therapy ; Hypertrophy, Left Ventricular / physiopathology ; Lipid Peroxidation / drug effects ; Lipid Peroxidation / physiology ; Long QT Syndrome / physiopathology ; Long QT Syndrome / prevention & control ; Male ; Oxidative Stress / physiology ; Prospective Studies ; Tetrazoles / therapeutic use ; Valine / pharmacology ; Valine / therapeutic use ; Valsartan Substance Nomenclature: 0 (Angiotensin II Type 1 Receptor Blockers) ; 0 (Antihypertensive Agents) ; 0 (Collagen Type I) ; 0 (Collagen Type III) ; 0 (Tetrazoles) ; 80M03YXJ7I (Valsartan) ; HG18B9YRS7 (Valine) Entry Date(s): Date Created: 20070602 Date Completed: 20070703 Latest Revision: 20151119 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.